This podcast is very relevant to pharmacists who frequently treat patients or interact with patients in pain. Not all pharmacists are intimately familiar with the FDA’s Opioid Analgesic Risk Evaluation and Mitigation Strategy (REMS), which is the official comprehensive pain education strategy essential to frontline providers in order to ensure that patients receive and understand the Medication Guides and information regarding safe use of opioid medications.
SPEAKERS
Suzanne Amato Nesbit, PharmD, BCPS, FCCP, FASHP is a Clinical Specialist in Pain Management and Palliative Care with the Department of Pharmacy and serves as the Residency Director for the PGY2 Pain Management and Palliative Care Pharmacy Residency at The Johns Hopkins Hospital in Baltimore, Maryland. She also currently serves on the ASHP Commission on Credentialing.
Chris Herndon, PharmD, BCACP, FASHP, FCCP is a Professor at Southern Illinois University Edwardsville (SIUE) School of Pharmacy. Dr. Herndon sees chronic pain and opioid use disorder patients within a family medicine residency clinic. Dr. Herndon’s scholarship interest focuses primarily on pain and palliative care education and he is the Principal Investigator for the National Institutes of Health Center of Excellence in Pain Education at SIUE. Dr. Herndon was president for the Society of Pain and Palliative Care Pharmacists in 2019, recipient of the Distinguished Service Award from the American Pain Society in 2018, and the Illinois Pharmacist’s Association’s “Pharmacist of the Year” in 2016.
Timothy J. Atkinson, PharmD, BCPS is a Clinical Pharmacy Specialist in Pain Management at the Veterans Affairs (VA) Tennessee Valley Healthcare System (TVHS) in Murfreesboro, Tennessee, where he specializes in complex and high-risk pain medication management through direct patient care and electronic consult services within the regional referral pain clinic. He also is Director of the ASHP-accredited PGY2 Pain Management and Palliative Care Residency program at TVHS and represents pain management on the national VA Residency Advisory Board.
Relevant Financial Relationship Disclosures
No one in control of the content of this activity has a relevant financial relationship (RFR) with an ineligible company.
As defined by the Standards of Integrity and Independence in Accredited Continuing Education definition of ineligible company.
This activity is supported by an independent educational grant from the Opioid Analgesic REMS Program Companies (RPC).
Please see https://www.opioidanalgesicrems.com/Resources/Docs/List_of_RPC_Companies.pdf for a listing of REMS Program Companies. This activity is intended to be fully compliant with the Opioid Analgesic REMS education requirements issued by the US Food & Drug Administration (FDA).